Sorrento Therapeutics, Inc., a clinical and commercial stage biopharmaceutical company, develops a portfolio of next-generation treatments for three therapeutic areas: cancer, infectious disease, and pain. It operates through two segments, Sorrento Therapeutics and Scilex.
The company provides cancer therapeutics by leveraging its proprietary G-MAB antibody library and targeted delivery modalities, which include chimeric antigen receptor T-cell therapy (CAR-T), dimeric antigen receptor T-cell therapy, and antibody drug conjugate, as well as a bispecific antibody approach. Additionally, it utilizes Sofusa, a drug delivery technology that delivers biologics directly into the lymphatic system.
Its clinical programs in development include anti-CD38 CAR-T therapy for the treatment of multiple myeloma, as well as for amyloidosis and graft versus host disease. The company develops resiniferatoxin, a non-opioid-based TRPV1 agonist neurotoxin for late-stage cancer and osteoarthritis pain treatment, and ZTlido, a lidocaine topical system for the treatment of post-herpetic neuralgia.
It engages in the development of SEMDEXA, an injectable viscous gel formulation, which is in Phase III trials for the treatment of sciatica, a pathology of low back pain; SP-103, an investigational non-aqueous lidocaine topical system undergoing clinical development in chronic low back pain conditions; and SP-104, a novel low-dose delayed-release naltrexone hydrochloride formulation for the treatment of fibromyalgia.
The company has collaborations with SmartPharm Therapeutics Inc. to develop a gene-encoded antibody vaccine to protect against COVID-19, and with Mayo Clinic for a Phase Ib pilot study using Sofusa lymphatic drug delivery technology to deliver Ipilimumab in patients with melanoma.
Sorrento Therapeutics was founded in 2006 and is based in San Diego, California. On February 13, 2023, Sorrento Therapeutics, Inc., along with its affiliate, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the Southern District of Texas. The plan was later approved as C.
